{"id":689079,"date":"2022-09-27T07:10:54","date_gmt":"2022-09-27T11:10:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\/"},"modified":"2022-09-27T07:10:54","modified_gmt":"2022-09-27T11:10:54","slug":"voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\/","title":{"rendered":"Voyager Therapeutics to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., Sept.  27, 2022  (GLOBE NEWSWIRE) &#8212; Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced that management will participate in the following investor conferences:<\/p>\n<ul type=\"disc\">\n<li>Chardan\u2019s 6th Annual Genetic Medicines Conference, New York, NY \u2013 Company presentation, October 4, 2022, 3:45 p.m. ET<\/li>\n<li>Truist Securities Genetic Medicine Summit, New York, NY \u2013 CNS panel discussion (not webcast), October 20, 2022<\/li>\n<\/ul>\n<p>The presentation may be accessed from the Investors section of Voyager\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nXK4p4DnKKV0PwuVrj86-vdn0GeZGll-ltNWN4TeZMcEEMEPnWZPSeGP3TKPuMsayx69YiWbIPixMH-zJZrZo4lltP4PnIYVsrQj9KAb9XLH_eWJCMVtZValGtEqjg8_\" rel=\"nofollow noopener\" target=\"_blank\">www.voyagertherapeutics.com<\/a>. Replays of webcasts are archived on the Company&#8217;s website for at least 30 days.<\/p>\n<p>\n        <strong>About<\/strong><br \/>\n        <strong>\u202f<\/strong><br \/>\n        <strong>Voyager Therapeutics<\/strong>\u00a0<br \/>Voyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the modality to treat devastating diseases. Proprietary capsids born from Voyager\u2019s TRACER capsid discovery platform are powering a rich early-stage pipeline of programs and may elevate the field to overcome the narrow therapeutic window associated with conventional gene therapy vectors across neurologic disorders and other therapeutic areas.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M5wilXEI1YkpmbH-znVASR5Q6mMn0m_EwVpTJOk2bzpWsNiiujVw2vxunNYPmicVXkV8Li-3H9D058qZju7Sq61HV4ngpUkSND3Cn8SXoGxguBOw76nfGb8daIpe6X8DIN4SUbpXyPWPSFM89b0EeIhdphONZ2EPrHWRoF6zM7zEhRIdilUtSOB-Z0KvT3y7x624nl5iw-EUGc9eXKqBdPFfwlzxo9PPzAzm_MYpvC_n_Ggy95Nw6eA0snWP_B6QQgyGygmEpW1N9F96zR7lbBxxaYXtgcsoD_hGWBufLpM=\" rel=\"nofollow noopener\" target=\"_blank\"><u>voyagertherapeutics.com<\/u><\/a>\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mKPORxkV6CnmQj7mplnc2cw6IMSdB6htcjLif76iHNZ91_F83vyVSrkAe99IfyHoZOnGzTuJwSGKz_k3GpP4lPPR_vAIriUReFkEa8aTKbwGKIv9eMLqtgyZOf4sN1JOJS74tB2OQE4pXfVoXGEJJ0Qu67Qf_QDqZKkoQzBSJUbN1V689tsBNMO5CxcTE4wnqFLG97u_gnRTB-a_jDAkK9d6iklea_hk8WX47CPfadl4ZThm1nqHXwx75Zafv0C30PYIrBZV37h20BsGP2tq-_EjYehB9UsLXmOizsAQFa_APu2euJWAQvgvvG_vXCmVgi5yFBYU11Rnl-tQhXhNGw==\" rel=\"nofollow noopener\" target=\"_blank\"><u>LinkedIn<\/u><\/a>\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RD6rRwpQrD6CKT1j4_BCRMiXa7__3Pq6H4ke1sZFbye3CPfo7dHxxid0qJiwWyJbY1_L7mzdWAWpYtpNmScJAHoQFG8jyWzSM1EtiAW0qtx2ADAzw1GD8ralANn2rUa9TNE9Se5580rvPRW1vpQ4nOcgM8BO_SJ-LXVhTmL3ubnY6PInGEq7nA6YtUfA6U0ifbgH-uKETczDvfXPTzAg5w==\" rel=\"nofollow noopener\" target=\"_blank\"><u>Twitter<\/u><\/a>\u00a0<\/p>\n<p>\n        <em>Voyager Therapeutics<\/em><br \/>\n        <sup><br \/>\n          <em>\u00ae<\/em><br \/>\n        <\/sup><br \/>\n        <em>\u00a0is a registered trademark, and TRACER\u2122 is a trademark, of\u00a0Voyager Therapeutics, Inc.<\/em>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzU1MSM1MTcyNTEyIzIwMTg4NDA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MTgxNDBkN2MtYmUyMy00ODk5LWI3NDMtMDAwNjIxNDIxNmVjLTEwMzA0MTM=\/tiny\/Voyager-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Contacts\u00a0\r\nInvestors\u00a0\r\nInvestors@voyagertherapeutics.com\u00a0\r\n\r\nMedia \u00a0\u00a0\r\nPeg Rusconi\u00a0\r\nprusconi@vergescientific.com\u00a0<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) &#8212; Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced that management will participate in the following investor conferences: Chardan\u2019s 6th Annual Genetic Medicines Conference, New York, NY \u2013 Company presentation, October 4, 2022, 3:45 p.m. ET Truist Securities Genetic Medicine Summit, New York, NY \u2013 CNS panel discussion (not webcast), October 20, 2022 The presentation may be accessed from the Investors section of Voyager\u2019s website at www.voyagertherapeutics.com. Replays of webcasts are archived on the Company&#8217;s website for at least 30 days. About \u202f Voyager Therapeutics\u00a0Voyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Voyager Therapeutics to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-689079","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Voyager Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Voyager Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) &#8212; Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced that management will participate in the following investor conferences: Chardan\u2019s 6th Annual Genetic Medicines Conference, New York, NY \u2013 Company presentation, October 4, 2022, 3:45 p.m. ET Truist Securities Genetic Medicine Summit, New York, NY \u2013 CNS panel discussion (not webcast), October 20, 2022 The presentation may be accessed from the Investors section of Voyager\u2019s website at www.voyagertherapeutics.com. Replays of webcasts are archived on the Company&#8217;s website for at least 30 days. About \u202f Voyager Therapeutics\u00a0Voyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock &hellip; Continue reading &quot;Voyager Therapeutics to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-27T11:10:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzU1MSM1MTcyNTEyIzIwMTg4NDA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Voyager Therapeutics to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2022-09-27T11:10:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\\\/\"},\"wordCount\":193,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MzU1MSM1MTcyNTEyIzIwMTg4NDA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\\\/\",\"name\":\"Voyager Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MzU1MSM1MTcyNTEyIzIwMTg4NDA=\",\"datePublished\":\"2022-09-27T11:10:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MzU1MSM1MTcyNTEyIzIwMTg4NDA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MzU1MSM1MTcyNTEyIzIwMTg4NDA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Voyager Therapeutics to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Voyager Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\/","og_locale":"en_US","og_type":"article","og_title":"Voyager Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) &#8212; Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced that management will participate in the following investor conferences: Chardan\u2019s 6th Annual Genetic Medicines Conference, New York, NY \u2013 Company presentation, October 4, 2022, 3:45 p.m. ET Truist Securities Genetic Medicine Summit, New York, NY \u2013 CNS panel discussion (not webcast), October 20, 2022 The presentation may be accessed from the Investors section of Voyager\u2019s website at www.voyagertherapeutics.com. Replays of webcasts are archived on the Company&#8217;s website for at least 30 days. About \u202f Voyager Therapeutics\u00a0Voyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock &hellip; Continue reading \"Voyager Therapeutics to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-27T11:10:54+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzU1MSM1MTcyNTEyIzIwMTg4NDA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Voyager Therapeutics to Participate in Upcoming Investor Conferences","datePublished":"2022-09-27T11:10:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\/"},"wordCount":193,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzU1MSM1MTcyNTEyIzIwMTg4NDA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\/","name":"Voyager Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzU1MSM1MTcyNTEyIzIwMTg4NDA=","datePublished":"2022-09-27T11:10:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzU1MSM1MTcyNTEyIzIwMTg4NDA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzU1MSM1MTcyNTEyIzIwMTg4NDA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-to-participate-in-upcoming-investor-conferences-4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Voyager Therapeutics to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/689079","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=689079"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/689079\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=689079"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=689079"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=689079"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}